¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"group hearing aid"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complementation group
    »óº¸¼ºÁý´Ü
  • control group
    ´ëÁ¶±º
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • end group
    ¸»´Ü±â
  • enteric group
    âÀÚ±Õ±º, Àå±Õ±º
  • functional group
    ÀÛ¿ë±â
  • glucophore group
    ´Ü¸À´Ü
  • group
    1. ±º, ¹«¸®, Áý´Ü 2. ±â 3. Á· 4. ±×·ì
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
  • group audiometry
    Áý´Üû·Â°Ë»ç
  • group displacement law
    Áý´Üº¯À§¹ýÄ¢
  • group dynamics
    Áý´Ü¿ªÇÐ, Áý´Ü¿ªµ¿
  • group fascicular repair
    ½Å°æ¼¶À¯´Ù¹ß±ººÀÇÕ(¼ú)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • central hearing loss
    ÁßÃßû·Â¼Ò½Ç, ÁßÃß³­Ã»
  • condensed milk conductive hearing loss
    ³óÃà¿ìÀ¯ÀüµµÃ»°¢¼Ò½Ç
  • conductive hearing loss
    Àüµµ³­Ã»
  • conductive hearing loss
    ÀüÀ½¼º³­Ã»
  • congenital hereditary hearing loss
    ¼±ÃµÀ¯Àü³­Ã»
  • hearing speech clinic
    û°¢¾ð¾îÁø·á¼Ò
  • double disharmonic hearing
    ÀÌÁßµè±â
  • hearing defect
    û°¢Àå¾Ö
  • hearing disorder
    û·ÂÀå¾Ö
  • hearing distance
    û·Â°Å¸®, °¡Ã»°Å¸®
  • hearing disturbance
    û·ÂÀå¾Ö
  • familial progressive hearing loss
    °¡Á·ÁøÇ೭û
  • functional hearing loss
    ±â´É³­Ã»
  • hearing
    µè±â, û°¢, û·Â
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • absolute hearing
    Àý´ëÀ½°¨
  • functional hearing loss
    ±â´É(¼º) ³­Ã»
  • hearing =audition
    û·Â, û°¢
  • hearing =audition
    û°¢(ôéÊÆ), û·Â(ôéæ³)
  • hearing acuity
    û·Â
  • hearing defect
    û·ÂÀå¾Ö
  • hearing disorder
    û·ÂÀå¾Ö
  • hearing disturbance
    û·ÂÀå¾Ö
  • hearing function
    û°¢±â´É
  • hearing island
    ûµµ
  • hearing loss
    °¨°¢½Å°æ(¼º) ³­Ã»
  • hearing loss
    ³­Ã», û·Â¼Ò½Ç, û·ÂÀå¾Ö
  • hearing loss, audiometric
    û·Â¼Õ½Ç
  • hearing loss, central
    ÁßÃß¼º û·Â¼Ò½Ç, ÁßÃß¼º ³­Ã»
  • hearing loss, conductive
    ÀüÀ½¼º ³­Ã», Àüµµ¼º ³­Ã»
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • speech aid
    ¹ßÀ½º¸Á¶±â(Û¡ëåÜÍð¾Ðï).
  • absolute hearing
    Àý´ëÀ½°¨
  • air conduction hearing
    ±âµµÃ»·Â
  • audibility test =hearing t.
    û·Â°Ë»ç, û·ÂÃøÁ¤
  • audiometric hearing loss
    û·Â¼Õ½Ç
  • audition =hearing
    û·Â, û°¢
  • auditory perception =a. sensation, a. sen se, sense of hearing
    û°¢(ôéÊÆ).
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú)
  • binaural hearing (effect)
    ¾çÀÌû(È¿°ú).
  • bone conduction hearing
    °ñµµÃ»·Â
  • central hearing loss
    ÁßÃß¼º û·Â¼Ò½Ç, ÁßÃß¼º ³­Ã»
  • central hearing loss
    ÁßÃß¼º û·Â»ó½Ç, ÁßÃß¼º ³­Ã».
  • condensed milk conductive hearing loss
  • conductive hearing loss
    ÀüÀ½¼º Àüµµ¼º ³­Ã»
  • congenital hearing loss
    ³­Ã»
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complementation group
    »óº¸±º(ßÓÜÍÏØ)
  • critical group
    ÀӰ豺(×üÍ£ÏØ)
  • diazo group
    µð¾ÆÁ¶ ±â(Ðñ)
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
  • glycolaldehyde group
    ±Û¶óÀÌÄݾ˵¥ÇÏÀ̵å±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HAE health appraisal examination; hearing aid evaluation; hepatic artery embolism; hereditary angioneuro...
HAM hearing aid microphone; helical axis in motion; human albumin microsphere; human alveolar macrophage...
ITC imidazolyl-thioguanine chemotherapy; Interagency Testing Committee; in the canal [hearing aid]
ITE insufficient therapeutic effect; in the ear [hearing aid]; in-training examination; intrapulmonary i...
SHAA serum hepatitis associated antigen; Society of Hearing Aid Audiologists
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AID Auto-immune diseases
LVA Low Vision Aid
C Group Control group
Group C Group
Group 2 Group 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monaural hearing
    ÀÏÀÌ Ã»°¢
  • sensorineural hearing loss
    °¨°¢ ½Å°æ¼º ³­Ã»
  • sensory hearing loss
    °¨°¢¼º ³­Ã»
    ¿Í¿ì
  • speech hearing test
    ¾îÀ½ û·Â °Ë»ç
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • allyl group
    ¾Ë¸±±º
  • axon group
    Ãà»è ±º
  • blood group
    Ç÷¾×Çü
    µ¿ÀǾî=blood ty
  • blood group incompatibility
    Ç÷¾×Çü ºÎÀûÇÕ
  • borderline group
    °æ°è ±º
  • chloramphenicol group antibiotics
    Ŭ·Î¶÷Æä´ÏÄݱº Ç×»ýÁ¦
  • coxsackie group A virus
    ÄÛ»èŰ A±º ¹ÙÀÌ·¯½º
    ¼öÆ÷¼º º´º¯ÀÎ Æ÷Áø¼º ±¸Çù¿°À» ¹ß»ý ½ÃŲ´Ù.
  • Coxsackie virus group A
    A±º ÄÛ»çŰ ¹ÙÀÌ·¯½º
  • E-blood group
    ÀÌ½Ä Ç÷¾×Çü
    »ç¶÷ÀÇ Ç÷¾×ÇüÀÇ Çϳª. OÇü ÀÌ¿ÜÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ Áß¿¡¼­ ¹ìÀå¾îÀÇ Ç÷û ¼Ó¿¡ Á¸ÀçÇÏ´Â ÀÀÁý¼Ò¿¡ °­ÇÏ°Ô ¹ÝÀÀÇÏ´Â °ÍÀ» EÇü, ¹ÝÀÀÀÌ ¾àÇÑ °ÍÀ» eÇüÀ¸·Î ÇÏ´Â Ç÷¾×ÇüÀ» ¸»ÇÑ´Ù. EÇüÀº ABO½ÄÀÇ BÇü¿¡ °¡Àå ¸¹°í, A, AB ¼øÀ¸·Î ºóµµ°¡ ³·´Ù. ¶ÇÇÑ À¯ÀüÀÚÇü°úµµ °ü°è°¡ ÀÖÀ¸¸ç II, II
  • herpes group of virus
    Æ÷Áø¼º ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
hearing loss, central Hearing loss due to central nervous system disease, anywhere in the auditory pathways from the cochlear nucleus of the pons to the auditory cortex.
(12 Dec 1998)
hearing loss, conductive Hearing loss due to interference with the acoustic transmission of sound to the cochlea. The interference is in the outer or middle ear.
(12 Dec 1998)
hearing loss, functional Hearing loss without a physical basis.
(12 Dec 1998)
hearing loss, high-frequency Hearing loss in frequencies above 1000 hertz.
(12 Dec 1998)
hearing loss, noise-induced Hearing loss from exposure to noise. The loss is often in the frequency range 4000-6000 hertz.
(12 Dec 1998)
hearing loss, partial A condition in which the sense of hearing, although defective, is functional with or without a hearing aid. The hearing level for speech is approximately 40-70 decibels I.s.o. (international organization for standardization) or 30-60 db a.s.a. (american standards association).
(12 Dec 1998)
hearing loss, sensorineural Hearing loss resulting from damage to the sensory mechanism internal from the oval and round windows.
(12 Dec 1998)
Helmholtz theory of hearing That the basilar membrane of the cochlea acts as a resonating structure, recording low tones from its apical turns and high tones from its basal turns.
Synonym: Helmholtz theory of hearing.
(05 Mar 2000)
sensorineural hearing loss <neurology> A form of deafness that occurs due to dysfunction of the auditory nerve (cranial nerve VIII).
(27 Sep 1997)
normal hearing The ability to perceive sound normally.
Synonym: normal hearing.
Origin: G. Akousis, hearing
(05 Mar 2000)
organ of hearing The content of the cochlea including the portion of the membranous labyrinth containing the spiral organ (cochlear duct) and the perilymphatic channels (scalae) which lie on either side.
Synonym: labyrinthus cochlearis, organ of hearing.
(05 Mar 2000)
ABO blood group <haematology> The major human blood type system which describes the oligosaccharide glycoprotein antigens found on the surface of human blood cells.
According to the type of antigen present, a person may be assigned a blood type of A, B, AB or O. A second type of antigen, the Rh factor, renders a positive or negative blood type. The ABO blood group system is important because it determines who can donate blood to or accept blood from whom.
Type A or AB blood will cause an immune reaction in people with type B blood and type B and AB blood will cause a reaction in people with type A blood.
Conversely, type O blood has no A or B antigens, so people with type O blood are universal donors.
And since AB blood already produces both antigens, people who are type AB can accept any of the other blood types without suffering an immune reaction.
(04 Jul 1999)
actinobacteria group A group of gram-positive, heterogeneous bacteria. This group encompasses a range of morphologically, physiologically, and chemically different organisms and includes bacteria that form cocci, short rods, irregular rods, and mycelia that fragment.
(12 Dec 1998)
alkyl group <chemistry> A funtional group on an organic molecule which is derived from an alkane which has lost a hydrogen atom.
(13 Nov 1997)
aluminum group Aluminum, boron, gallium, indium, and thallium.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • age-group
    ¿¬·É Áý´Ü
  • group
    Áý´Ü,¶¼¸¦ Áþ´Ù,ºÐ·ùÇÏ´Ù
  • Group of 77
    77°³±¹ ±×·ì(UNÀÇ ¹«¿ª°³¹ß ȸÀÇ(UNCTAD)ÀÇ È¸¿øÀÎ ¹ßÀü µµ»ó±¹ ±×·ì)
  • Group of Seven
    G;7 ¼±Áø 7°³±¹ ±×·ì
  • blood group
    Ç÷¾×Çü Á¤
  • code group
    ºÎÈ£±º
  • continuous group
    ¿¬¼Ó±º
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • enxounter group
    (Á¤ÀÇ)Áý´Ü °¨¼ö¼º ÈÆ·Ã ±×·ì
  • ethnic group
    (»çȸ)ÀÎÁ¾ Áý´Ü
  • focus group
    Æ÷Ä¿½º ±×·ì(Å×½ºÆ®ÇÒ »óǰ¿¡ ´ëÇØ¼­ ÅäÀÇÇÏ´Â ¼ÒºñÀÚ ±×·ì)
  • fringe group
    ºñÁÖ·ùÆÄ
  • front group
    (À§ÀåÇÑ) Ç¥¸é»óÀÇ Á¶Á÷(´Üü)
  • ginger group
    (Á¤´ç µûÀ§ Á¶Á÷ ³»ºÎÀÇ)Çõ½ÅÆÄ
  • group
    ¹«¸®;ºñÇà ´ë´ë;ºñÇà ¿¬´ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á